GJIC
TEVA icon

Gamble Jones Investment Counsel’s Teva Pharmaceuticals TEVA Stock Holding History

Gamble Jones Investment Counsel’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-6,566
Closed -$302K – 207
2016
Q3 		$302K Buy
6,566
+3
+0% +$157 0.03% 181
2016
Q2 		$330K Buy
6,563
+2
+0% +$106 0.04% 181
2016
Q1 		$351K Sell
6,561
-122
-2% -$7.16K 0.04% 174
2015
Q4 		$439K Sell
6,683
-1,893
-22% -$117K 0.05% 169
2015
Q3 		$484K Sell
8,576
-123
-1% -$7.97K 0.06% 166
2015
Q2 		$514K Sell
8,699
-73
-0.8% -$4.5K 0.05% 171
2015
Q1 		$547K Sell
8,772
-298
-3% -$17.3K 0.06% 161
2014
Q4 		$522K Sell
9,070
-498
-5% -$27.7K 0.05% 166
2014
Q3 		$514K Buy
9,568
+3
+0% +$159 0.06% 163
2014
Q2 		$501K Sell
9,565
-481
-5% -$24.6K 0.06% 168
2014
Q1 		$531K Sell
10,046
-797
-7% -$36.8K 0.06% 157
2013
Q4 		$435K Sell
10,843
-2,722
-20% -$107K 0.05% 167
2013
Q3 		$512K Sell
13,565
-2,397
-15% -$93.5K 0.07% 156
2013
Q2 		$626K Buy
+15,962
New +$622K 0.08% 142

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Gamble Jones Investment Counsel's TEVA Position: Q4 2016 in Review

Gamble Jones Investment Counsel sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 6,566 shares — an estimated $302K sold.

Gamble Jones Investment Counsel first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $626K in Q2 2013. 738 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • Gamble Jones Investment Counsel reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Gamble Jones Investment Counsel sold 6,566 Teva Pharmaceuticals shares in Q4 2016, an estimated $302K.
  • Gamble Jones Investment Counsel first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Gamble Jones Investment Counsel's Teva Pharmaceuticals position peaked at $626K in Q2 2013.
  • 738 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Gamble Jones Investment Counsel's 13F filing for Q4 2016, filed 26 Jan 2017.